cavosonstat: Clinical Trials

4 trials of cavosonstat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 unknown. 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 24Completed 2, Unknown 2

Follow cavosonstat: new trials by email Literature Review of cavosonstat trials Research Report on cavosonstat

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)
placebo, Cavosonstat 5 mg, Cavosonstat 10 mg - Chronic Obstructive Pulmonary Disease (COPD)
Phase 2UnknownGSNOR Therapeutics, Inc.1082021-02-032020-10-23
PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study
MCT, Clazakizumab, Broncho-Vaxom - Asthma
Phase 2CompletedUniversity of North Carolina, Chapel Hill9502019-12-192026-04-01
Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor
Cavosonstat, Placebo - Cystic Fibrosis
Phase 2UnknownNivalis Therapeutics, Inc.192016-04-012016-11-21
Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation
Cavosonstat, Placebo - Cystic Fibrosis
Phase 2CompletedNivalis Therapeutics, Inc.1382015-11-012017-01-10

Conditions studied

Cystic Fibrosis (2)  ·  Asthma (1)  ·  Pulmonary Disease, Chronic Obstructive (1)

Sponsors

Nivalis Therapeutics, Inc. (2)  ·  GSNOR Therapeutics, Inc. (1)  ·  University of North Carolina, Chapel Hill (1)

Countries

United States (3)

Top investigators

Anastasia Ivanova, PhD (1)  ·  James Chmiel, MD (1)  ·  Scott Donaldson, MD (1)

NIH funding

U24HL138998 (1)